Literature DB >> 34739043

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.

Noa Eliakim-Raz1, Yaara Leibovici-Weisman1, Amos Stemmer2, Asaf Ness1, Muhammad Awwad1, Nassem Ghantous1, Salomon M Stemmer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34739043      PMCID： PMC8652594          DOI： 10.1001/jama.2021.19885

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  6 in total

1.  Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses.

Authors:  Ilies Benotmane; Gabriela Gautier; Peggy Perrin; Jérôme Olagne; Noëlle Cognard; Samira Fafi-Kremer; Sophie Caillard
Journal:  JAMA       Date:  2021-07-23       Impact factor: 56.272

2.  Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.

Authors:  Einav G Levin; Yaniv Lustig; Carmit Cohen; Ronen Fluss; Victoria Indenbaum; Sharon Amit; Ram Doolman; Keren Asraf; Ella Mendelson; Arnona Ziv; Carmit Rubin; Laurence Freedman; Yitshak Kreiss; Gili Regev-Yochay
Journal:  N Engl J Med       Date:  2021-10-06       Impact factor: 91.245

3.  COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.

Authors:  Ugur Sahin; Alexander Muik; Evelyna Derhovanessian; Isabel Vogler; Lena M Kranz; Mathias Vormehr; Alina Baum; Kristen Pascal; Jasmin Quandt; Daniel Maurus; Sebastian Brachtendorf; Verena Lörks; Julian Sikorski; Rolf Hilker; Dirk Becker; Ann-Kathrin Eller; Jan Grützner; Carsten Boesler; Corinna Rosenbaum; Marie-Cristine Kühnle; Ulrich Luxemburger; Alexandra Kemmer-Brück; David Langer; Martin Bexon; Stefanie Bolte; Katalin Karikó; Tania Palanche; Boris Fischer; Armin Schultz; Pei-Yong Shi; Camila Fontes-Garfias; John L Perez; Kena A Swanson; Jakob Loschko; Ingrid L Scully; Mark Cutler; Warren Kalina; Christos A Kyratsous; David Cooper; Philip R Dormitzer; Kathrin U Jansen; Özlem Türeci
Journal:  Nature       Date:  2020-09-30       Impact factor: 49.962

4.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

Authors:  Edward E Walsh; Robert W Frenck; Ann R Falsey; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; Kathleen Neuzil; Mark J Mulligan; Ruth Bailey; Kena A Swanson; Ping Li; Kenneth Koury; Warren Kalina; David Cooper; Camila Fontes-Garfias; Pei-Yong Shi; Özlem Türeci; Kristin R Tompkins; Kirsten E Lyke; Vanessa Raabe; Philip R Dormitzer; Kathrin U Jansen; Uğur Şahin; William C Gruber
Journal:  N Engl J Med       Date:  2020-10-14       Impact factor: 91.245

5.  Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection.

Authors:  Raymond A Harvey; Jeremy A Rassen; Carly A Kabelac; Wendy Turenne; Sandy Leonard; Reyna Klesh; William A Meyer; Harvey W Kaufman; Steve Anderson; Oren Cohen; Valentina I Petkov; Kathy A Cronin; Alison L Van Dyke; Douglas R Lowy; Norman E Sharpless; Lynne T Penberthy
Journal:  JAMA Intern Med       Date:  2021-05-01       Impact factor: 21.873
  6 in total
  47 in total

1.  Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?

Authors:  Masaaki Takeuchi; Akina Esaki; Yukie Higa; Akemi Nakazono
Journal:  PLoS One       Date:  2022-06-17       Impact factor: 3.752

2.  BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages.

Authors:  Bernd Jahrsdörfer; Matthias Proffen; Judith Scholz; Janina Hägele; Carolin Ludwig; Christiane Vieweg; Aline Grempels; Dorit Fabricius; Ramin Lotfi; Sixten Körper; Guido Adler; Hubert Schrezenmeier
Journal:  Front Immunol       Date:  2022-06-20       Impact factor: 8.786

3.  Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers.

Authors:  Arianna Pani; Alessandra Romandini; Alice Schianchi; Michele Senatore; Oscar M Gagliardi; Gianluca Gazzaniga; Stefano Agliardi; Tommaso Conti; Paolo A Schenardi; Matteo Maggi; Stefano D'Onghia; Valentina Panetta; Silvia Renica; Silvia Nerini Molteni; Chiara Vismara; Daniela Campisi; Michaela Bertuzzi; Simona Giroldi; Laura Zoppini; Mauro Moreno; Marco Merli; Marco Bosio; Massimo Puoti; Francesco Scaglione
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

4.  Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern.

Authors:  Mandy Schwarze; Andor Krizsan; Alexandra Brakel; Fabian Pohl; Daniela Volke; Ralf Hoffmann
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

5.  Safety and immunogenicity of synchronous COVID19 and influenza vaccination.

Authors:  Andreina Baj; Daniela Dalla Gasperina; Daniele Focosi; Greta Forlani; Francesca Drago Ferrante; Federica Novazzi; Lorenzo Azzi; Fabrizio Maggi
Journal:  J Clin Virol Plus       Date:  2022-05-07

6.  Facilitators and Barriers to Take up a COVID-19 Vaccine Booster Dose among Community-Dwelling Older Adults in Hong Kong: A Population-Based Random Telephone Survey.

Authors:  Zixin Wang; Yuan Fang; Fuk-Yuen Yu; Paul Shing-Fong Chan; Siyu Chen; Fenghua Sun
Journal:  Vaccines (Basel)       Date:  2022-06-17

7.  Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.

Authors:  Avishay Spitzer; Yoel Angel; Or Marudi; David Zeltser; Esther Saiag; Hanoch Goldshmidt; Ilana Goldiner; Moshe Stark; Ora Halutz; Ronni Gamzu; Marina Slobodkin; Nadav Amrami; Eugene Feigin; Meital Elbaz; Moran Furman; Yotam Bronstein; Amanda Chikly; Anna Eshkol; Victoria Furer; Talia Mayer; Suzy Meijer; Ariel Melloul; Michal Mizrahi; Michal Yakubovsky; Dana Rosenberg; Ari Safir; Liron Spitzer; Eyal Taleb; Ori Elkayam; Adi Silberman; Tali Eviatar; Ofir Elalouf; Tal Levinson; Katia Pozyuchenko; Ayelet Itzhaki-Alfia; Eli Sprecher; Ronen Ben-Ami; Oryan Henig
Journal:  JAMA       Date:  2022-01-25       Impact factor: 157.335

8.  Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication.

Authors:  Naoki Tani; Hideyuki Ikematsu; Takeyuki Goto; Kei Gondo; Takeru Inoue; Yuki Yanagihara; Yasuo Kurata; Ryo Oishi; Junya Minami; Kyoko Onozawa; Sukehisa Nagano; Hiroyuki Kuwano; Koichi Akashi; Nobuyuki Shimono; Yong Chong
Journal:  Open Forum Infect Dis       Date:  2022-09-23       Impact factor: 4.423

9.  Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients.

Authors:  Noa Berar-Yanay; Sarit Freiman; Maʹanit Shapira; Amer Saffoury; Ameer Elemy; Munir Hamze; Mohamad Elhaj; Maha Zaher; Loai Matanis; Zaher Anis Armaly
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

10.  Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.

Authors:  Evangelos Terpos; Maria Gavriatopoulou; Ioannis Ntanasis-Stathopoulos; Alexandros Briasoulis; Sentiljana Gumeni; Panagiotis Malandrakis; Eleni-Dimitra Papanagnou; Magdalini Migkou; Nikolaos Kanellias; Efstathios Kastritis; Ioannis P Trougakos; Meletios A Dimopoulos
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.